180 related articles for article (PubMed ID: 35508511)
21. LIM Domain Only 2 Regulates Endothelial Proliferation, Angiogenesis, and Tissue Regeneration.
Meng S; Matrone G; Lv J; Chen K; Wong WT; Cooke JP
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792641
[TBL] [Abstract][Full Text] [Related]
22. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
23. Elucidation of the role of LMO2 in human erythroid cells.
Inoue A; Fujiwara T; Okitsu Y; Katsuoka Y; Fukuhara N; Onishi Y; Ishizawa K; Harigae H
Exp Hematol; 2013 Dec; 41(12):1062-76.e1. PubMed ID: 24041784
[TBL] [Abstract][Full Text] [Related]
24. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
25. Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.
Landry JR; Bonadies N; Kinston S; Knezevic K; Wilson NK; Oram SH; Janes M; Piltz S; Hammett M; Carter J; Hamilton T; Donaldson IJ; Lacaud G; Frampton J; Follows G; Kouskoff V; Göttgens B
Blood; 2009 Jun; 113(23):5783-92. PubMed ID: 19171877
[TBL] [Abstract][Full Text] [Related]
26. SCL/TAL1 in Hematopoiesis and Cellular Reprogramming.
Hoang T; Lambert JA; Martin R
Curr Top Dev Biol; 2016; 118():163-204. PubMed ID: 27137657
[TBL] [Abstract][Full Text] [Related]
27. The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype.
Chan WY; Follows GA; Lacaud G; Pimanda JE; Landry JR; Kinston S; Knezevic K; Piltz S; Donaldson IJ; Gambardella L; Sablitzky F; Green AR; Kouskoff V; Göttgens B
Blood; 2007 Mar; 109(5):1908-16. PubMed ID: 17053063
[TBL] [Abstract][Full Text] [Related]
28. [Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia].
Meng YS; Wei R; Ai GW; Meng XQ; Zhang YX
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):890-3. PubMed ID: 19671288
[TBL] [Abstract][Full Text] [Related]
29. A novel role for
Chiu SK; Saw J; Huang Y; Sonderegger SE; Wong NC; Powell DR; Beck D; Pimanda JE; Tremblay CS; Curtis DJ
Development; 2018 Oct; 145(19):. PubMed ID: 30185409
[TBL] [Abstract][Full Text] [Related]
30. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.
Valge-Archer VE; Osada H; Warren AJ; Forster A; Li J; Baer R; Rabbitts TH
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8617-21. PubMed ID: 8078932
[TBL] [Abstract][Full Text] [Related]
31. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.
Ferrando AA; Neuberg DS; Staunton J; Loh ML; Huard C; Raimondi SC; Behm FG; Pui CH; Downing JR; Gilliland DG; Lander ES; Golub TR; Look AT
Cancer Cell; 2002 Feb; 1(1):75-87. PubMed ID: 12086890
[TBL] [Abstract][Full Text] [Related]
32. Lyl1 interacts with CREB1 and alters expression of CREB1 target genes.
San-Marina S; Han Y; Suarez Saiz F; Trus MR; Minden MD
Biochim Biophys Acta; 2008 Mar; 1783(3):503-17. PubMed ID: 18160048
[TBL] [Abstract][Full Text] [Related]
33. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
Ferrando AA; Herblot S; Palomero T; Hansen M; Hoang T; Fox EA; Look AT
Blood; 2004 Mar; 103(5):1909-11. PubMed ID: 14604958
[TBL] [Abstract][Full Text] [Related]
34. Shared roles for
Chiu SK; Orive SL; Moon MJ; Saw J; Ellis S; Kile BT; Huang Y; Chacon D; Pimanda JE; Beck D; Hamilton JR; Tremblay CS; Curtis DJ
Blood; 2019 Sep; 134(10):826-835. PubMed ID: 31300405
[TBL] [Abstract][Full Text] [Related]
35. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
36. Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.
Ryan DP; Duncan JL; Lee C; Kuchel PW; Matthews JM
Proteins; 2008 Mar; 70(4):1461-74. PubMed ID: 17910069
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
38. The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
O'Connor KW; Kishimoto K; Kuzma IO; Wagner KP; Selway JS; Roderick JE; Karna KK; Gallagher KM; Hu K; Liu H; Li R; Brehm MA; Zhu LJ; Curtis DJ; Tremblay CS; Kelliher MA
Leukemia; 2024 May; 38(5):951-962. PubMed ID: 38553571
[TBL] [Abstract][Full Text] [Related]
39. LDB1 Enforces Stability on Direct and Indirect Oncoprotein Partners in Leukemia.
Layer JH; Christy M; Placek L; Unutmaz D; Guo Y; Davé UP
Mol Cell Biol; 2020 May; 40(12):. PubMed ID: 32229578
[TBL] [Abstract][Full Text] [Related]
40. LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
Morishima T; Krahl AC; Nasri M; Xu Y; Aghaallaei N; Findik B; Klimiankou M; Ritter M; Hartmann MD; Gloeckner CJ; Stefanczyk S; Lindner C; Oswald B; Bernhard R; Hähnel K; Hermanutz-Klein U; Ebinger M; Handgretinger R; Casadei N; Welte K; Andre M; Müller P; Bajoghli B; Skokowa J
Blood; 2019 Oct; 134(14):1159-1175. PubMed ID: 31366618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
